Verition Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.87M | Buy |
51,506
+4,474
| +10% | +$163K | 0.01% | 1491 |
|
|
2025
Q1 | $1.7M | Sell |
47,032
-238,009
| -83% | -$8.62M | 0.01% | 1296 |
|
|
2024
Q4 | $12M | Buy |
285,041
+207,735
| +269% | +$8.74M | 0.05% | 387 |
|
|
2024
Q3 | $4.29M | Sell |
77,306
-60,125
| -44% | -$3.34M | 0.02% | 703 |
|
|
2024
Q2 | $5.65M | Buy |
137,431
+21,506
| +19% | +$884K | 0.03% | 501 |
|
|
2024
Q1 | $5.41M | Buy |
115,925
+108,855
| +1,540% | +$5.08M | 0.04% | 487 |
|
|
2023
Q4 | $338K | Buy |
+7,070
| New | +$338K | ﹤0.01% | 1333 |
|
|
2023
Q3 | – | Sell |
-7,507
| Closed | -$346K | – | 2213 |
|
|
2023
Q2 | $346K | Buy |
7,507
+1,166
| +18% | +$53.8K | ﹤0.01% | 1256 |
|
|
2023
Q1 | $254K | Buy |
6,341
+1,294
| +26% | +$51.9K | ﹤0.01% | 1489 |
|
|
2022
Q4 | $234K | Sell |
5,047
-6,316
| -56% | -$293K | ﹤0.01% | 1289 |
|
|
2022
Q3 | $471K | Buy |
+11,363
| New | +$471K | 0.01% | 1526 |
|
|
2022
Q2 | – | Sell |
-89,483
| Closed | -$6.5M | – | 2373 |
|
|
2022
Q1 | $6.5M | Buy |
+89,483
| New | +$6.5M | 0.08% | 197 |
|
|
2021
Q3 | – | Sell |
-38,948
| Closed | -$3.71M | – | 1972 |
|
|
2021
Q2 | $3.71M | Buy |
+38,948
| New | +$3.71M | 0.03% | 241 |
|
|
2020
Q1 | – | Sell |
-15,793
| Closed | -$675K | – | 860 |
|
|
2019
Q4 | $675K | Buy |
+15,793
| New | +$675K | 0.01% | 476 |
|
|
2019
Q2 | – | Sell |
-9,378
| Closed | -$650K | – | 1199 |
|
|
2019
Q1 | $650K | Buy |
+9,378
| New | +$650K | 0.03% | 500 |
|